Aspira Pathlab & Diagnostics Ltd. Hits Upper Circuit on BSE, 21 September 2026
- September 21, 2026
- Posted by: Kunal Singla
- Category: News
On 21 September 2026, Aspira Pathlab & Diagnostics Ltd. (ASPIRA) hit the upper circuit on BSE at Rs 120.75, a 5% positive move from the previous close of Rs 115. The company’s market cap stood at Rs 118.37 crore. The upper circuit price for the session was Rs 120.75.
The move was driven by buying interest against the exchange-defined price band. At the time of writing the stock was locked at its upper circuit level, which makes the session worth noting for short-term market participants.
Key Takeaways
- Aspira Pathlab & Diagnostics Ltd. (ASPIRA) hit the upper circuit on BSE at Rs 120.75 on 21 September 2026.
- The session move was +5% against a previous close of Rs 115.
- Market capitalisation stood at Rs 118.37 crore with a PE ratio of 49.34.
- No official company announcement or verified catalyst was confirmed at the time of writing.
- A price band is an exchange trading rule, not a view on the company or a recommendation.
Key Market Data
| Metric | Value |
|---|---|
| Stock | Aspira Pathlab & Diagnostics Ltd. |
| Current Price / LTP | Rs 120.75 |
| Day Move | 5% |
| Previous Close | Rs 115 |
| Day Open | Rs 120.75 |
| Day High | Rs 120.75 |
| Day Low | Rs 120.75 |
| Upper Circuit Price | Rs 120.75 |
| Upper Circuit Limit | Rs 120.75 |
| Market Cap | Rs 118.37 crore |
| Selected Exchange | BSE |
| PE Ratio | 49.34 |
All figures above are as of 21 September 2026, sourced from Univest market data for the BSE listing. Only fields present in the source for this session are shown.
Price Action and Trading Activity
Aspira Pathlab & Diagnostics Ltd. opened at Rs 120.75 on BSE, compared with a previous close of Rs 115. During the session, the stock traded between Rs 120.75 and Rs 120.75 before touching the upper circuit price of Rs 120.75.
The absolute day change was Rs 5.75, while the percentage move was 5%. The event figures are kept to a single exchange so the numbers stay comparable.
The selected exchange matters because price bands, day range, and previous-close values can differ across exchanges. This article uses BSE consistently for the event table and narrative. The stated upper circuit limit for the session was Rs 120.75, which is the level the price reached.
Why Aspira Pathlab & Diagnostics Ltd. Hit Upper Circuit
Aspira Pathlab & Diagnostics Ltd. hit the upper circuit after buying interest pushed the stock to its exchange-defined price band. No official company announcement or verified external catalyst was confirmed at the time of writing, so the move should be read primarily through price action and market sentiment.
Because no verified catalyst was available, this article does not attribute the move to earnings, corporate action, sector news, or market rumours. If a confirmed announcement becomes available later, it should be added as a separate update.
Within the session the stock reached the upper circuit level of Rs 120.75.
What the Upper Circuit Means
An upper circuit is the maximum price level a stock is allowed to reach during a trading session under the applicable exchange price band. For Aspira Pathlab & Diagnostics Ltd., the captured upper circuit price was Rs 120.75 on 21 September 2026.
The circuit mechanism is meant to slow extreme price movement and keep trading orderly. It is a market-structure fact, not a return forecast. In this article, the upper circuit explains what happened in the session and where the price band was reached.
Aspira Pathlab & Diagnostics Ltd. Fundamentals and Valuation
Available market data gives a fuller picture than price action alone. For Aspira Pathlab & Diagnostics Ltd., PE ratio was 49.34, PB ratio was 9.37, book value was Rs 12.28, EPS was 2.33, ROE was 18.13%, ROCE was 19.27%, dividend yield was 0% and debt-to-assets ratio was 0.1, on a market cap of Rs 118.37 crore. These are available financial indicators and should not be read as a buy, sell, or hold view.
A PB ratio above 1 means the market price was above the reported book value per share. That premium can reflect growth expectations, asset quality, or simply thin trading in a smaller counter.
For investors tracking upper circuit moves, these metrics help separate the price event from the broader financial profile. A sharp one-day move can attract attention, but valuation and return ratios still need to be reviewed separately.
Peer and Sector Context
Aspira Pathlab & Diagnostics Ltd. belongs to the Hospital & Healthcare Services industry within the Healthcare sector. The peer table below uses available companies from the same sector or industry to give broader valuation context.
| Peer Company | Market Cap | PE | PB | ROE |
|---|---|---|---|---|
| Dr Agarwals Eye Hospital Ltd. | Rs 2598.44 crore | 34.09 | 7.03 | 36.29% |
| KMC Speciality Hospitals (India) Ltd. | Rs 2452.8 crore | 43.98 | 10.81 | 31.61% |
| Krsnaa Diagnostics Ltd. | Rs 1756.55 crore | 18.02 | 1.78 | 10.02% |
| SURAKSHA DIAGNOSTIC LIMITED | Rs 1750.17 crore | 48.89 | 6.82 | 13.93% |
| Shalby Ltd. | Rs 1488.91 crore | 37.87 | 1.47 | 6.31% |
Several of these peers are far larger by market capitalisation than Aspira Pathlab & Diagnostics Ltd. Size differences change liquidity and cost of capital, so the table is sector context rather than a like-for-like ranking.
Aspira Pathlab & Diagnostics Ltd.’s PE ratio was 49.34, compared with an available peer/sector PE average of 36.57, calculated from the 5 peer companies that had a PE on record. This comparison is a valuation reference point, not a recommendation.
Technical and Ownership Snapshot
The technical snapshot adds context: RSI was 55.33, the 50-day moving average was 95.04 and the 200-day moving average was 87.93.
Shareholding details were not available in the latest market dataset, so no conclusion is drawn about promoter, institutional, or public-shareholder activity.
What Readers Should Know
The main confirmed fact is that Aspira Pathlab & Diagnostics Ltd. hit the upper circuit on BSE at Rs 120.75 on 21 September 2026, with a 5% day move.
The practical limitation after an upper-circuit session is execution. Buyers queue at the band and sellers step back, so the quoted price is not necessarily a price you can transact at. The other limitation is that no official catalyst was confirmed at the time of writing.
Readers should treat upper circuit events as market updates, not standalone investment conclusions. The price band shows strong near-term interest, but follow-up analysis should consider business fundamentals, valuation, liquidity, risk, and confirmed company disclosures.
Frequently Asked Questions
Why did Aspira Pathlab & Diagnostics Ltd. hit upper circuit on 21 September 2026?
The stock reached its upper price band after buying interest during the session. No official company announcement or verified external catalyst was confirmed at the time of writing.
What was ASPIRA share price on 21 September 2026?
The last traded price used in this article was Rs 120.75 on BSE. That price matched the upper circuit price captured for the event.
What was the upper circuit price for ASPIRA?
The upper circuit price was Rs 120.75. The stated exchange upper circuit limit was Rs 120.75. The event numbers in this article are aligned to BSE.
What is Aspira Pathlab & Diagnostics Ltd.’s market cap and PE ratio?
Aspira Pathlab & Diagnostics Ltd.’s market cap was Rs 118.37 crore. PE ratio was 49.34.
Which exchange and data source were used?
The selected exchange was BSE. The article uses Univest market data available at the time of generation, captured on 21 September 2026.
Does hitting an upper circuit mean Aspira Pathlab & Diagnostics Ltd. is a buy or a sell?
No. A circuit is an exchange price-band rule that caps how far a stock can move in a single session. It carries no view on valuation or business quality and is not a recommendation. Any decision should rest on fundamentals, valuation, liquidity and your own risk tolerance.
Can you buy or sell Aspira Pathlab & Diagnostics Ltd. shares when the stock is at the upper circuit?
It is usually difficult. At the upper circuit, buy orders queue up while sellers step back, so there may be no counterparty at the quoted price. Orders can stay unfilled until the band opens up or sellers return.
What happens the next trading session after an upper circuit?
There is no fixed outcome. The band resets each session, so the stock can open freely, hit the same band again, or reverse. The exchange can also revise the applicable band width. The useful signals to watch are whether the company files any disclosure explaining the move.
What is the upper circuit limit set at for Indian stocks?
Exchange price bands are commonly set at 2%, 5%, 10% or 20% depending on the security, and the applicable band can be revised by the exchange. For Aspira Pathlab & Diagnostics Ltd. the stated limit was Rs 120.75. For this session, Aspira Pathlab & Diagnostics Ltd. moved 5%.
Footer Disclosure
This article is for informational purposes only and does not constitute investment advice. Research services are provided by Uniapps Investment Adviser Pvt. Ltd., a wholly owned subsidiary of Univest, SEBI RIA registration number INA000017639.
